Temel İstatistikler
| CIK | 356591 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Neurologix, Inc.
SEC Filings (Chronological Order)
Bu sayfa, başka bir yerde sunduğumuz mülkiyet başvuruları hariç, SEC Dosyalarının tam ve kronolojik bir listesini sunmaktadır.
| April 29, 2019 |
NRGXQ / Neurologix, Inc. REVOKED begin 644 filename1 M)5!$1BTQ+C8-)>+CS],-"[email protected] P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q M,S$Y-3DO3R X-S$O12 V.#@S+TX@-B]4(#$S,34R,R]((%L@-#%LX-CD@ M,C!=+TEN9F\@.#8X(# @4B],96YG=&@@-C@O4')E=B Q,S$U,C0O4F]O=" X M-S @,"!2+U-I>F4@.#@Y+U1Y<&4O6%)E9B]76S$@,B Q73X^(ZPUJC[5-HV! MP>RU ^NL[7W-\'1&MK[G X-'!U-' W-' T,'6T0!7!];/4/4'2',!L0!( M@-&+@9^!@46 XP:W@LV!O ,S&NXR9;&P/W!SAEUC8-!A]D=K$^0@7%9#9#F M9&#P? UWC0S0G9 |
|
| February 16, 2016 |
NRGXQ / Neurologix, Inc. / Medtronic plc - SC 13D/A AMENDMENT NO. 2 Activist Investment SC 13D/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Neurologix, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of S |
|
| February 21, 2013 |
NRGXQ / Neurologix, Inc. / Medtronic Inc - SCHEDULE 13D AMENDMENT NO.1 Activist Investment Schedule 13D Amendment No.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Neurologix, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class o |
|
| March 23, 2012 |
v306914ex9-1 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| March 23, 2012 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2012 NEUROLOGIX, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-13347 06-1582875 (State or Other Jurisdiction of Incorporation (Commission File Number) |
|
| March 21, 2012 |
Bankruptcy or Receivership - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2012 NEUROLOGIX, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-13347 06-1582875 (State or Other Jurisdiction of Incorporation (Commission File Number) |
|
| February 17, 2012 | ||
| February 17, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2012 NEUROLOGIX, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-13347 06-1582875 (State or Other Jurisdiction of Incorporation (Commission File Numb |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2012 NEUROLOGIX, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-13347 06-1582875 (State or Other Jurisdiction of Incorporation (Commission File Numb |
|
| January 27, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2012 NEUROLOGIX, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-13347 06-1582875 (State or Other Jurisdiction of Incorporation (Commission File Numbe |
|
| January 27, 2012 |
NEUROLOGIX, INC. January 26, 2012 Michael G. Kaplitt, M.D., Ph.D. Department of Neurosurgery Weill Medical College of Cornell University 525 E. 68th Street New York, NY 10021 Re: Amendment to Consulting Agreement Dear Dr. Kaplitt: This letter (this “Amendment”) effective as of January 26, 2012, amends that certain Amended and Restated Consulting Agreement, dated as of April 25, 2005 (as amended, r |
|
| January 27, 2012 |
NEUROLOGIX, INC. January 25, 2012 Matthew J. During, M.D., D.Sc. Professor and Director The Ohio State University Human Cancer Genetics Program BRT 912, 460 West 12th Street Columbus, OH 43210 Re: Amendment to Consulting Agreement Dear Dr. During: This letter (this “Amendment”) effective as of January 25, 2012, amends that certain Consulting Agreement, dated as of October 1, 1999 (as amended, rest |
|
| January 27, 2012 |
NEUROLOGIX, INC. January 23, 2012 Mr. Reginald Hardy 2600 Southwest Third Avenue, Suite 950 Miami, FL 33129 Re: Amendment to Employment Agreement Dear Reg: This letter (this “Amendment”), effective as of January 23, 2012, amends that certain letter agreement, dated as of December 15, 2011 (as amended, restated, supplemented or otherwise modified from time to time, the “Employment Agreement”), by a |
